Article

Analysis of the Prognostic Factors for the Long-Term Survival in Patients of Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

2024-12-04

Abstract excerpt

<h4>Background: </h4> In recent years, immune checkpoint inhibitors (ICIs) have been introduced as a first-line treatment for patients with non-small cell lung cancer (NSCLC), which are expected to achieve long-term survival. However, despite ICI treatment, many patients do not achieve sustained effects from immunotherapy. To date, detailed studies on the long-term survival in patients with NSCLC without driver ge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 582a23d0-bab3-5015-817f-b5f6b8d81518
DOI: 10.22541/au.173331561.11402109/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Analysis of the Prognostic Factors for the Long-Term Survival in Patients of Non-small Cell Lung Cancer Treated with Immune Checkpoint InhibitorsDOI 10.22541/au.173331561.11402109/v1Read

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read

Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity Read

Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.Semantic proximity Read

Association of Lymphocyte Subsets in Advanced Non-Small Cell Lung Cancer Patients with the Efficacy and Prognosis of Immune Checkpoint Inhibitor Therapy: A Retrospective StudySemantic proximity Read

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors Following Disease Progression or RelapseSemantic proximity Read

Efficacy of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR-mutationsSemantic proximity Read

Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.Semantic proximity Read

Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.Semantic proximity Read

Periphery TH/TS ratio and TP53 mutation predict the efficacy of ICI-based therapy in advanced non-small cell lung cancer with high PD-L1 expressionSemantic proximity Read

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read

High Lymphocyte Population-related Predictive Factors for a Long-term Response in Non-small Cell Lung Cancer Patients Treated with Pemetrexed: A Retrospective Observational StudySemantic proximity Read

Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessationSemantic proximity Read